Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18999456 | TARGETING THE PVR AXIS USING CAR T CELL THERAPY AND COMBINATIONS | December 2024 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 18904578 | ABSOLUTE PRECIPITATION OF EXOSOMES (APEX) ISOLATION | October 2024 | February 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18735079 | METHOD FOR ANALYZING CONTENT AND DISTRIBUTION OF MICROPLASTICS IN MARINE CNIDARIA ORGANISMS | June 2024 | January 2025 | Allow | 7 | 1 | 0 | No | No |
| 18589909 | UTERINE-DERIVED REGENERATIVE CELL COMPOSITIONS AND USES THEREOF | February 2024 | January 2025 | Allow | 10 | 2 | 1 | Yes | No |
| 18442444 | Non-Human Animals Expressing Humanized CD3 Complex | February 2024 | June 2025 | Allow | 16 | 0 | 1 | Yes | No |
| 18410576 | ABSOLUTE PRECIPITATION OF EXOSOMES (APEX) ISOLATION | January 2024 | September 2024 | Allow | 8 | 1 | 0 | No | No |
| 18541448 | GENERATION OF ALVEOLAR EPITHELIAL TYPE 1 (AT1) CELLS | December 2023 | February 2025 | Allow | 14 | 2 | 1 | Yes | No |
| 18562767 | AGENT FOR IMPROVING CANCER CACHEXIA AND METHOD FOR IMPROVING CANCER CACHEXIA | November 2023 | December 2024 | Abandon | 13 | 1 | 0 | Yes | No |
| 18316688 | RECOMBINANT CONSTRUCTS AND TRANSGENIC FLUORESCENT ORNAMENTAL FISH THEREFROM | May 2023 | February 2025 | Allow | 21 | 2 | 0 | No | No |
| 18187268 | TRANSDUCED T CELLS EXPRESSING HUMAN SSTR2 AND APPLICATION THEREOF | March 2023 | February 2025 | Allow | 23 | 2 | 0 | No | No |
| 18156205 | ASSAY FOR DRUG DISCOVERY BASED ON IN VITRO DIFFERENTIATED CELLS | January 2023 | March 2025 | Allow | 26 | 1 | 0 | Yes | No |
| 18081476 | RETINAL PIGMENT EPITHELIUM CELL COMPOSITIONS | December 2022 | January 2025 | Abandon | 25 | 3 | 1 | Yes | No |
| 18064441 | AGENT FOR ACCELERATING GROWTH OF PLURIPOTENT STEM CELLS | December 2022 | February 2025 | Allow | 27 | 2 | 0 | Yes | No |
| 18055312 | STEM CELL DERIVED ISLET DIFFERENTIATION | November 2022 | November 2023 | Allow | 12 | 2 | 1 | Yes | No |
| 17932915 | CRISPR-CAS10 SYSTEMS AND METHODS FOR PHAGE GENOME EDITING | September 2022 | June 2025 | Allow | 33 | 0 | 0 | No | No |
| 17943348 | HOMOGENIZATION METHOD OF INFECTING A MOSQUITO WITH WOLBACHIA | September 2022 | April 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 17906145 | READY-TO-USE FLY NEONATE LARVAE WITH EXTENDED SHELF-LIFE AND METHODS OF PRODUCING SAME | September 2022 | June 2025 | Allow | 33 | 3 | 1 | Yes | No |
| 17895405 | KIT AND METHOD FOR CONSTRUCTING LONG-ACTING DEPRESSION ANIMAL MODEL | August 2022 | February 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 17886067 | SYSTEMS AND METHODS FOR CELL CULTURING | August 2022 | April 2025 | Allow | 32 | 1 | 1 | No | No |
| 17844757 | Method For Promoting Differentiation Of Pluripotent Stem Cells By Reducing Undifferentiated State Thereof | June 2022 | June 2024 | Allow | 24 | 0 | 0 | No | No |
| 17830278 | ENGINEERED CELLS WITH IMPROVED PROTECTION FROM NATURAL KILLER CELL KILLING | June 2022 | September 2023 | Abandon | 16 | 1 | 1 | No | No |
| 17680843 | CHIMERIC GENE CONSTRUCTS FOR GENERATION OF FLUORESCENT TRANSGENIC ORNAMENTAL FISH | February 2022 | November 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17677208 | Toxicity Management for Anti-Tumor Activity of CARs | February 2022 | December 2024 | Abandon | 33 | 1 | 0 | No | No |
| 17673453 | RNA ENGINEERED T CELLS FOR THE TREATMENT OF CANCER | February 2022 | May 2025 | Abandon | 39 | 1 | 1 | No | No |
| 17671312 | IN VITRO PROLIFERATION MEDIUM, IN VITRO CULTURE KIT AND IN VITRO PROLIFERATION CULTURE METHOD OF UMBILICAL CORD BLOOD (UCB)-DERIVED NATURAL KILLER (NK) CELLS | February 2022 | May 2025 | Abandon | 39 | 4 | 0 | No | No |
| 17666334 | METHOD OF GENERATING HEPATIC CELLS | February 2022 | June 2025 | Allow | 40 | 2 | 1 | No | No |
| 17622364 | METHOD OF PREPARING MOUSE MODEL OF HERPES | December 2021 | April 2025 | Allow | 40 | 1 | 0 | No | No |
| 17557525 | TISSUE-DERIVED TISSUEGENIC IMPLANTS, AND METHODS OF FABRICATING AND USING SAME | December 2021 | May 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17552720 | METHODS FOR MODIFYING THE GROWTH RATE OF A CELL | December 2021 | March 2025 | Abandon | 39 | 2 | 0 | No | No |
| 17542997 | METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES | December 2021 | April 2024 | Abandon | 28 | 4 | 0 | No | No |
| 17543020 | METHODS FOR DETECTING AND MODULATING THE EMBRYONIC-FETAL TRANSITION IN MAMMALIAN SPECIES | December 2021 | April 2024 | Abandon | 28 | 4 | 0 | No | No |
| 17529686 | Amplifiable RNAs for Therapeutic Cell Systems | November 2021 | October 2024 | Abandon | 35 | 0 | 1 | No | No |
| 17528936 | RED TRANSGENIC FLUORESCENT ORNAMENTAL FISH | November 2021 | December 2024 | Allow | 37 | 2 | 0 | Yes | No |
| 17528827 | TARGETED CANCER THERAPY | November 2021 | February 2025 | Abandon | 39 | 0 | 1 | No | No |
| 17511092 | METHODS AND COMPOSITIONS FOR MONITORING AND ENHANCING EARLY EMBRYO DEVELOPMENT | October 2021 | April 2025 | Abandon | 41 | 2 | 0 | No | No |
| 17506730 | NON-HUMAN ANIMALS EXPRESSING HUMANIZED C1Q COMPLEX | October 2021 | September 2024 | Allow | 35 | 2 | 1 | Yes | No |
| 17504502 | BLOOD TYPE O Rh- HYPO-IMMUNOGENIC CELLS | October 2021 | April 2025 | Allow | 41 | 1 | 1 | Yes | No |
| 17503143 | METHODS FOR GENERATING STEM CELL-DERIVED BETA CELLS AND METHODS OF USE THEREOF | October 2021 | June 2024 | Allow | 32 | 1 | 0 | No | No |
| 17498110 | GENE EDITING OF REPRODUCTIVE HORMONES TO REDUCE FERTILITY IN ICTALURUS PUNCTATUS | October 2021 | January 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17493533 | MACS-BASED PURIFICATION OF STEM CELL-DERIVED RETINAL PIGMENT EPITHELIUM | October 2021 | October 2024 | Allow | 37 | 1 | 1 | No | No |
| 17482991 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD137 | September 2021 | August 2024 | Abandon | 34 | 1 | 0 | No | No |
| 17439184 | MODIFIED ADENOVIRUS AND MEDICINE COMPRISING SAME | September 2021 | April 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17427449 | USE OF MOUSE MODEL IN EVALUATION OF INTELLIGENCE LEVEL | July 2021 | March 2025 | Allow | 43 | 5 | 0 | Yes | No |
| 17444009 | PLATELET-RICH PLASMA COMPOSITIONS AND METHODS OF PREPARATION | July 2021 | September 2024 | Abandon | 37 | 1 | 0 | No | No |
| 17385039 | HUMANIZED IL-6 AND IL-6 RECEPTOR | July 2021 | October 2024 | Allow | 39 | 2 | 1 | Yes | No |
| 17368933 | NON-HUMAN ANIMAL EXHIBITING DIMINISHED UPPER AND LOWER MOTOR NEURON FUNCTION AND SENSORY PERCEPTION | July 2021 | August 2024 | Abandon | 37 | 1 | 1 | No | No |
| 17358774 | GENE AND CELL THERAPY USING CELL FUSION TECHNOLOGY | June 2021 | April 2024 | Allow | 33 | 1 | 0 | Yes | No |
| 17416044 | EMBRYONIC ERYTHROBLAST-CONTAINING CELL POPULATION AND METHOD FOR PRODUCING SAME, CELL CULTURE COMPOSITION, AND COMPOUND TEST METHOD | June 2021 | November 2024 | Allow | 41 | 1 | 1 | Yes | No |
| 17338795 | Purification and Purity Assessment of RNA Molecules Synthesized with Modified Nucleosides | June 2021 | March 2024 | Allow | 33 | 1 | 0 | Yes | No |
| 17328980 | SCALABLE PRIMATE PLURIPOTENT STEM CELL AGGREGATE SUSPENSION CULTURE | May 2021 | October 2024 | Allow | 41 | 2 | 0 | Yes | No |
| 17316494 | CANCER SCREENING AND THERAPEUTICS | May 2021 | January 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17241651 | USE OF RNA FOR REPROGRAMMING SOMATIC CELLS | April 2021 | April 2025 | Allow | 47 | 5 | 1 | No | No |
| 17240373 | LYMPHANGIOGENESIS-PROMOTING AGENTS | April 2021 | September 2024 | Abandon | 41 | 1 | 1 | No | No |
| 17206451 | METHOD OF GENERATING HEPATIC CELLS | March 2021 | November 2021 | Allow | 7 | 1 | 1 | Yes | No |
| 17201977 | METHODS FOR MAKING AND USING MODIFIED OOCYTES | March 2021 | March 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17173563 | Vip3A RESISTANT SPODOPTERA FRUGIPERDA | February 2021 | November 2024 | Abandon | 45 | 3 | 1 | Yes | No |
| 17168603 | GENETICALLY MODIFIED NON-HUMAN ANIMAL WITH HUMAN OR CHIMERIC CD3e | February 2021 | February 2024 | Allow | 36 | 1 | 1 | Yes | No |
| 17161376 | METHOD FOR IDENTIFYING, EXPANDING, AND REMOVING ADULT STEM CELLS AND CANCER STEM CELLS | January 2021 | January 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17131887 | HUMAN IPSC-BASED DERIVATION OF NK AND T-CELLS USING EARLY NOTCH INDUCTION | December 2020 | May 2023 | Allow | 29 | 3 | 2 | Yes | No |
| 17254725 | OPTIMIZED CLN5 GENES AND EXPRESSION CASSETTES AND THEIR USE | December 2020 | September 2024 | Allow | 45 | 1 | 1 | Yes | No |
| 17118241 | Non-Human Animals Expressing Humanized CD3 Complex | December 2020 | November 2023 | Allow | 35 | 1 | 1 | Yes | No |
| 17118045 | THERAPEUTIC AGENTS | December 2020 | June 2023 | Allow | 30 | 1 | 0 | No | No |
| 16972118 | PHARMACEUTICAL COMPOSITION COMPRISING MESENCHYMAL STEM CELLS AS EFFECTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF INFLAMMATORY DISEASE | December 2020 | March 2025 | Allow | 51 | 5 | 0 | No | No |
| 17059059 | CAR NK CELLS | November 2020 | February 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17089409 | METHODS OF GENERATING ENUCLEATED ERYTHROID CELLS USING MYO-INOSITOL | November 2020 | January 2024 | Abandon | 38 | 0 | 1 | No | No |
| 17074970 | SYSTEMS AND METHODS FOR CELL CULTURING | October 2020 | April 2022 | Allow | 18 | 4 | 0 | Yes | No |
| 17047937 | ENRICHMENT OF GENOME-EDITED CELLS | October 2020 | February 2025 | Abandon | 52 | 1 | 1 | No | No |
| 17064920 | MUTATIONS IN RHODOPSIN GENE IN ZEBRAFISH AND USES THEREOF | October 2020 | April 2023 | Allow | 31 | 0 | 0 | No | No |
| 17062362 | METHOD OF TREATING A MAMMAL WITH DIABETES ASSOCIATED KIDNEY DISEASE USING LOCAL ADMINISTRATION OF STEM CELLS WITH TRANSIENTLY REDUCED p53 | October 2020 | January 2025 | Abandon | 51 | 2 | 1 | No | No |
| 16963074 | METHOD FOR PREPARING NON-HUMAN PRIMATE SOMATIC CELL CLONED ANIMAL | September 2020 | May 2024 | Allow | 46 | 2 | 1 | Yes | No |
| 17025057 | METHODS FOR SELECTIVE INHIBITION OF PLURIPOTENT STEM CELLS | September 2020 | December 2023 | Allow | 39 | 1 | 0 | Yes | No |
| 16979640 | METHODS AND COMPOSITIONS FOR INDUCIBLE EXPRESSION OF NEUROTROPHIC FACTORS | September 2020 | November 2024 | Allow | 50 | 3 | 1 | No | No |
| 17013143 | UNIVERSAL DONOR CELLS | September 2020 | May 2021 | Allow | 8 | 1 | 1 | Yes | No |
| 17012599 | METHOD FOR REDUCING IMMUNOGENICITY OF RNA | September 2020 | August 2023 | Allow | 35 | 1 | 1 | No | No |
| 17002252 | Interferon Production Using Short RNA Duplexes | August 2020 | January 2024 | Allow | 41 | 0 | 1 | No | No |
| 16969929 | ENGINEERED IMMUNE CELLS AS DIAGNOSTIC PROBES OF DISEASE | August 2020 | April 2024 | Abandon | 44 | 0 | 1 | No | No |
| 16991076 | METHOD FOR PRODUCING ADENOHYPOPHYSIS OR PRECURSOR TISSUE THEREOF | August 2020 | June 2024 | Allow | 46 | 2 | 1 | No | No |
| 16967917 | TREATMENT OF DEAFNESS BY GENE THERAPY | August 2020 | August 2024 | Abandon | 48 | 1 | 0 | No | No |
| 16966521 | TRANSCRIPTION REGULATORY ELEMENTS AND USES THEREOF | July 2020 | January 2025 | Allow | 53 | 1 | 1 | Yes | No |
| 16965568 | MODIFIED MONOCYTES/MACROPHAGES/DENDRITIC CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS AND USES IN DISEASES AND DISORDERS ASSOCIATED WITH PROTEIN AGGREGATES | July 2020 | September 2024 | Abandon | 50 | 2 | 1 | No | No |
| 16963880 | EXPRESSION VECTOR AND METHOD | July 2020 | January 2025 | Allow | 54 | 2 | 1 | No | No |
| 16928774 | CELL CULTURE DEVICE AND CELL CULTURE METHOD | July 2020 | April 2025 | Abandon | 57 | 2 | 1 | No | No |
| 16960441 | METHOD FOR PRODUCING CARDIOMYOCYTES | July 2020 | July 2023 | Allow | 36 | 2 | 1 | Yes | No |
| 16960285 | METHOD FOR GENETIC MANIPULATION OF SAP-FEEDING INSECTS | July 2020 | November 2024 | Allow | 52 | 2 | 1 | No | No |
| 16919456 | NOVEL AND EFFICIENT METHOD FOR REPROGRAMMING BLOOD TO INDUCED PLURIPOTENT STEM CELLS | July 2020 | January 2024 | Allow | 43 | 2 | 0 | Yes | No |
| 16917464 | METHOD FOR PRODUCING NA�VE PLURIPOTENT STEM CELLS | June 2020 | November 2023 | Abandon | 40 | 0 | 1 | No | No |
| 16916836 | GENE AND CELL THERAPY USING CELL FUSION TECHNOLOGY | June 2020 | August 2023 | Allow | 37 | 2 | 0 | No | No |
| 16915859 | RECOMBINANT CONSTRUCTS AND TRANSGENIC FLUORESCENT ORNAMENTAL FISH THEREFROM | June 2020 | February 2023 | Allow | 31 | 1 | 0 | No | No |
| 16899540 | USE OF HAPLOTYPE OF SNP SITE ASSOCIATED WITH HYPOXIA TOLERANCE IN BREEDING OF MEGALOBRAMA AMBLYCEPHALA | June 2020 | March 2024 | Abandon | 45 | 2 | 0 | Yes | No |
| 16892181 | FUNCTIONAL OLIGODENDROCYTES DERIVED FROM PLURIPOTENT STEM CELLS AND METHODS OF MAKING AND USING THE SAME | June 2020 | July 2023 | Allow | 37 | 1 | 0 | Yes | No |
| 16892000 | MIDBRAIN DOPAMINE (DA) NEURONS FOR ENGRAFTMENT | June 2020 | November 2023 | Allow | 42 | 1 | 1 | Yes | No |
| 16882147 | TARGETED DELIVERY OF GLYCINE RECEPTORS TO EXCITABLE CELLS | May 2020 | March 2023 | Allow | 34 | 1 | 0 | No | No |
| 16878362 | GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS FOR PRODUCING HEAVY CHAIN-ONLY ANTIBODIES | May 2020 | July 2023 | Allow | 38 | 1 | 1 | No | No |
| 16877008 | THERAPEUTIC AGENTS | May 2020 | October 2020 | Allow | 5 | 1 | 0 | Yes | No |
| 16877035 | THERAPEUTIC AGENTS | May 2020 | August 2020 | Allow | 3 | 0 | 0 | Yes | No |
| 16877294 | DEVELOPMENT OF SUPERIOR CHIMERISM BY hiPSC ENGINEERING AND EMBRYO AGGREGATION | May 2020 | August 2023 | Allow | 38 | 1 | 1 | Yes | No |
| 16875486 | STEM CELL SUBPOPULATIONS WITH DIFFERENTIAL GSTT1 EXPRESSION OR GENOTYPE | May 2020 | July 2023 | Allow | 38 | 2 | 1 | No | No |
| 16872226 | Non-Human Animals Expressing Humanized CD3 Complex | May 2020 | July 2020 | Allow | 2 | 0 | 0 | No | No |
| 16870959 | BLOOD TYPE O Rh- HYPO-IMMUNOGENIC PLURIPOTENT CELLS | May 2020 | July 2021 | Allow | 15 | 2 | 1 | Yes | No |
| 16857855 | METHOD FOR PRODUCING CHIMERIC ANIMAL | April 2020 | July 2023 | Allow | 39 | 2 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BERTOGLIO, VALARIE E.
With a 18.2% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 17.9% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner BERTOGLIO, VALARIE E works in Art Unit 1632 and has examined 1,062 patent applications in our dataset. With an allowance rate of 54.9%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.
Examiner BERTOGLIO, VALARIE E's allowance rate of 54.9% places them in the 10% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by BERTOGLIO, VALARIE E receive 2.32 office actions before reaching final disposition. This places the examiner in the 79% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by BERTOGLIO, VALARIE E is 36 months. This places the examiner in the 16% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +42.2% benefit to allowance rate for applications examined by BERTOGLIO, VALARIE E. This interview benefit is in the 90% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 19.5% of applications are subsequently allowed. This success rate is in the 12% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 42.8% of cases where such amendments are filed. This entry rate is in the 58% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
When applicants request a pre-appeal conference (PAC) with this examiner, 25.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 26% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 83.1% of appeals filed. This is in the 73% percentile among all examiners. Of these withdrawals, 72.2% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 8.8% of allowed cases (in the 95% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.